Meta Expands AI Training With Employee Activity Tracking Tools 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
NEW YORK, March 20, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of BioAmber Inc. (“BioAmber”) (NYSE:BIOA) (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra/bioamber-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period BioAmber made materially false and/or misleading statements and/or failed to disclose that: (1) a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017; and (2) as a result, defendants’ statements about BioAmber’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in BioAmber you have until May 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
